Debt to Capital Ratio: A measurement of a company's financial leverage, calculated as the company's long-term debt divided by its total capital. Calculated as: Total Long-Term Debt / (Total Long-Term Debt + Shareholders Equity)
Ligand Pharmaceuticals Incorporated (LGND) had Debt to Capital Ratio of 0.31 for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$51.72M |
|
$-13.35M |
|
$3.27M |
|
$48.45M |
|
$34.35M |
|
$17.37M |
|
$-41.63M |
|
$-24.26M |
|
$-28.13M |
|
$-13.35M |
|
$-13.35M |
|
$-13.35M |
|
$-18.95M |
|
$17.37M |
|
$24.89M |
|
19.88M |
|
19.88M |
|
$-0.67 |
|
$-0.67 |
|
| Balance Sheet Financials | |
$865.41M |
|
-- |
|
$666.69M |
|
$1.53B |
|
$40.67M |
|
$446.90M |
|
$494.12M |
|
$534.78M |
|
$997.32M |
|
$678.44M |
|
$997.32M |
|
20.03M |
|
| Cash Flow Statement Financials | |
$48.69M |
|
$-94.35M |
|
$-14.13M |
|
$174.93M |
|
$115.09M |
|
$-59.83M |
|
$10.60M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
21.28 |
|
-- |
|
-- |
|
|
Debt to Capital Ratio |
0.31 |
0.45 |
|
93.67% |
|
33.58% |
|
33.58% |
|
-- |
|
-46.90% |
|
-25.80% |
|
$48.46M |
|
-- |
|
-- |
|
-- |
|
0.03 |
|
0.25 |
|
0.94 |
|
95.35 |
|
-1.34% |
|
-1.97% |
|
-0.87% |
|
-0.92% |
|
$49.79 |
|
$2.44 |
|
$2.45 |
|